| Literature DB >> 27268050 |
Jing Shi1, Jun Tang1, Dapeng Chen2.
Abstract
BACKGROUND: The aim of this study was to systematically evaluate the diagnostic performance of nCD64 for neonatal sepsis.Entities:
Keywords: Diagnosis; Meta-analysis; Neonatal sepsis; Neutrophil CD64
Mesh:
Substances:
Year: 2016 PMID: 27268050 PMCID: PMC4897921 DOI: 10.1186/s13052-016-0268-1
Source DB: PubMed Journal: Ital J Pediatr ISSN: 1720-8424 Impact factor: 2.638
Fig. 1The process of the study selection
Characteristics of included studies
| ID | Author | Year | Area | n | Episodes of sepsis | Infected/noninfected | Diagnosis standard | Type of sepsis | Infants | nCD64 analysis | Analysis cut-off | TP | FP | FN | TN |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Bhandari | 2008 [ | USA | 163 | 293 | 128/165 | Clinical or proven | b | Preterm | FCM | 2.30* | 90 | 63 | 38 | 102 |
| 2 | Dilli | 2010 [ | Turkey | 109 | 109 | 35/74 | Clinical or proven | c | Preterm + term | FCM | 4.39* | 31 | 11 | 4 | 63 |
| 3 | Genel | 2012 [ | Turkey | 119 | 119 | 49/70 | Clinical or proven | c | Preterm + term | FCM | 3.05 MFI | 40 | 16 | 9 | 54 |
| 4 | Groselj-Grenc | 2009 [ | Slovenia | 46 | 46 | 17/29 | Clinical or proven | c | Preterm + term | FCM | 1.86* | 13 | 6 | 4 | 23 |
| 5 | Lam | 2011 [ | China | 310 | 310 | 136/174 | Clinical or proven | a | Preterm + term | FCM | 6010 $ | 107 | 37 | 29 | 137 |
| 6 | Motta | 2014 [ | Italy | 129 | 129 | 48/81 | Clinical or proven | a | Preterm | FCM | 2.4* | 31 | 12 | 17 | 69 |
| 7 | Ng | 2004 [ | China | 359 | 359 | 115/244 | Clinical or proven | a | Term | FCM | 5500 $ | 93 | 46 | 22 | 198 |
| 8 | Ng | 2006 [ | China | 298 | 298 | 93/205 | Clinical or proven | a | Term | FCM | 6136 $ | 73 | 20 | 20 | 185 |
| 9 | Zeitoun | 2010 [ | USA | 98 | 98 | 49/49 | Clinical or proven | c | Preterm + term | FCM | 2.6* | 45 | 14 | 4 | 35 |
| 10 | Du | 2014 [ | China | 158 | 158 | 88/70 | Clinical | a | Preterm | FCM | 1010 $ | 72 | 21 | 16 | 49 |
| 11 | Elawady | 2014 [ | Egypt | 50 | 50 | 25/25 | Clinical | b | Preterm + term | FCM | 46.0 | 24 | 0 | 1 | 24 |
| 12 | Layseca-Espinosa | 2002 [ | Mexico | 29 | 29 | 14/15 | Clinical | c | Preterm + term | FCM | # | 3 | 0 | 11 | 15 |
| 13 | Streimish(a) | 2014 [ | USA | 684 | 1156 | 207/416 | Clinical | a | Preterm | FCM | 1.63 | 139 | 137 | 68 | 279 |
| 14 | Streimish(b) | 2014 [ | USA | 204/329 | Clinical | b | Preterm | FCM | 2.19 | 159 | 135 | 45 | 194 | ||
| 15 | Choo | 2012 [ | Korea | 23 | 23 | 11/12 | Proven | c | Preterm + term | FCM | 3.0* | 10 | 2 | 1 | 10 |
| 16 | Elawady | 2014 [ | Egypt | 50 | 50 | 25/25 | Proven | b | Preterm + term | FCM | 45.8 | 24 | 0 | 1 | 25 |
| 17 | Layseca-Espinosa | 2002 [ | Mexico | 34 | 34 | 17/17 | Proven | c | Preterm + term | FCM | # | 5 | 1 | 12 | 16 |
| 18 | Ng | 2002 [ | China | 110 | 147 | 37/110 | Proven | b | Preterm | FCM | 4000 $ | 35 | 13 | 2 | 97 |
| 19 | Soni | 2013 [ | India | 60 | 60 | 24/36 | Proven | c | Preterm + term | FCM | 2.765* | 22 | 12 | 2 | 24 |
| 20 | Streimish(a) | 2012 [ | USA | 649 | 997 | 3/577 | Proven | a | Preterm | FCM | 2.38 | 3 | 185 | 0 | 392 |
| 21 | Streimish(b) | 2012 [ | USA | 47/370 | Proven | b | Preterm | FCM | 3.62 | 35 | 85 | 12 | 285 |
a, early-onset; b, late-onset; c, early & late-onset; *, CD64 index; FCM, flow cytometric technology; MFI: mean fluorescence intensity; Clinical infection defined as infection suspected on a clinical basis; proven infection defined as culture-proven infection with an identified micro-organism; #, Arithmetic mean + 3 SD of the percentage of CD64 + cells found in normal neonates; $: cAntibody-phycoerythrin molecules bound per cell
Quality assessment of the included articles
| Studies | QUADAS list item | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | |
| Bhandari, 2008 [ | + | 0 | + | + | + | + | + | + | 0 | 0 | + | + | 0 | + |
| Choo, 2012 [ | + | - | + | + | + | + | + | + | 0 | 0 | + | + | - | + |
| Dilli, 2010 [ | + | + | + | + | + | + | + | + | + | 0 | + | 0 | + | + |
| Du, 2014 [ | + | + | + | + | + | + | + | + | - | + | + | + | 0 | + |
| Elawady, 2014 [ | + | + | + | + | + | + | + | + | + | 0 | + | 0 | + | + |
| Genel, 2012 [ | + | + | + | + | + | + | + | + | 0 | 0 | + | 0 | + | + |
| Groselj-Grenc, 2009 [ | + | 0 | + | + | + | + | + | + | + | 0 | + | + | + | + |
| Lam, 2011 [ | + | 0 | + | + | + | + | + | + | + | + | + | + | 0 | + |
| Layseca-Espinosa, 2002 [ | + | 0 | + | + | + | + | + | - | + | 0 | + | 0 | 0 | + |
| Motta, 2014 [ | + | - | + | + | + | + | + | + | + | 0 | + | 0 | + | + |
| Ng, 2002 [ | - | + | + | + | + | + | + | + | 0 | 0 | + | 0 | + | + |
| Ng, 2004 [ | + | + | + | + | + | + | + | + | + | 0 | + | + | + | + |
| Ng, 2006 [ | + | + | + | + | + | + | + | + | + | 0 | + | + | + | + |
| Soni, 2013 [ | + | 0 | + | + | + | + | + | + | + | 0 | + | + | + | + |
| Streimish, 2012 [ | + | 0 | + | + | + | + | + | + | 0 | 0 | + | + | 0 | + |
| Streimish, 2014 [ | + | 0 | + | + | + | + | + | + | 0 | 0 | + | + | 0 | + |
| Zeitoun, 2010 [ | + | + | + | + | + | + | + | + | 0 | 0 | + | 0 | 0 | + |
Abbreviation: QUADAS Quality Assessment of Diagnostic Accuracy Studies. +: YES; -: NO; 0: not clear
Fig. 2The forest plots of sensitivity (a) and specificity (b) of neutrophil CD64 for neonatal sepsis diagnosis
Fig. 3The forest plots of positive likelihood ratio (a) and negative likelihood ratio (b) of neutrophil CD64 for neonatal sepsis diagnosis
Fig. 4The diagnostic odds ratio (DOR) (a) and the summary receiver operating characteristic (SROC) (b) curve
Subgroup analyses
| Subgroup | Studies | Sensitivity (95 %) | Specificity (95 %) | PLR (95 %) | NLR (95 %) | SDOR (95 %) | AUC | Q* |
|---|---|---|---|---|---|---|---|---|
| All | 21 | 0.77 (0.74, 0.79) | 0.74 (0.72, 0.75) | 3.58 (2.85, 4.49) | 0.29 (0.22, 0.37) | 15.18 (9.75, 23.62) | 0.8666 | 0.7972 |
| Infection | ||||||||
| Proven | 7 | 0.82 (0.75, 0.87) | 0.74 (0.71, 0.77) | 4.14 (2.56, 6.68) | 0.17 (0.06, 0.52) | 30.58 (9.75, 95.88) | 0.9136 | 0.8461 |
| Clinical | 5 | 0.74 (0.70, 0.77) | 0.66 (0.62, 0.69) | 2.19 (1.72, 2.79) | 0.39 (0.25, 0.62) | 6.98 (3.68, 13.24) | 0.8245 | 0.7576 |
| Clinical or Proven | 9 | 0.78 (0.75, 0.81) | 0.79 (0.77, 0.82) | 3.93 (2.81, 5.49) | 0.27 (0.21, 0.36) | 15.41 (8.76, 27.09) | 0.8661 | 0.7967 |
| Type of sepsis | ||||||||
| Early-onset | 7 | 0.75 (0.72, 0.78) | 0.74 (0.72, 0.76) | 3.57 (2.49, 5.11) | 0.31 (0.23, 0.42) | 12.40 (6.40, 24.00) | 0.8415 | 0.7732 |
| Late-onset | 6 | 0.79 (0.75, 0.82) | 0.71 (0.68, 0.74) | 3.42 (2.11, 5.55) | 0.24 (0.14, 0.41) | 18.86 (6.82, 52.16) | 0.9262 | 0.8606 |
| Early & late-onset | 8 | 0.78 (0.72, 0.84) | 0.79 (0.74, 0.84) | 3.65 (2.93, 4.57) | 0.26 (0.11, 0.59) | 20.43 (12.31, 33.91) | 0.8835 | 0.8140 |
| Infants | ||||||||
| Preterm | 8 | 0.74 (0.71, 0.77) | 0.69 (0.67, 0.71) | 2.76 (2.16, 3.54) | 0.37 (0.30, 0.47) | 7.83 (4.84, 12.68) | 0.8088 | 0.7436 |
| Term | 2 | 0.80 (0.74, 0.85) | 0.85 (0.82, 0.88) | 5.75 (3.08, 10.72) | 0.24 (0.18, 0.31) | 24.07 (13.17, 44.01) | -- | -- |
| Preterm + term | 11 | 0.81 (0.76, 0.84) | 0.81 (0.78, 0.84) | 3.88 (3.04, 4.97) | 0.21 (0.11, 0.41) | 22.84 (12.94, 40.29) | 0.8853 | 0.8159 |
Meta-regression
| Variances | Coeff. | Std. Err. |
| RDOR | [95 % CI] |
|---|---|---|---|---|---|
| Cte. | 1.002 | 0.729 | 0.1883 | ---- | ---- |
| S | 0.094 | 0.1956 | 0.6375 | ---- | ---- |
| sepsis | -0.319 | 0.3179 | 0.3298 | 0.73 | (0.37;1.43) |
| infants | 0.806 | 0.2946 | 0.0147 | 2.24 | (1.20;4.18) |
| diagnosis | 0.436 | 0.2814 | 0.1406 | 1.55 | (0.85;2.81) |